Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The US Drug Pricing Hearing Pharma Wants

Executive Summary

Senate hearing will examine drug delivery system, but industry still faces possibility of another public shaming about increasing drug costs.

You may also be interested in...



Trump Drug Pricing Plan May Include Rebate Pass-Through Push – Novartis CEO

Industry exec Jimenez hopes President Trump’s reform proposals, expected in next three months, will include measures to ensure manufacturer rebates are passed through to patients and encourage outcomes-based reimbursement contracts with payers.

The Latest Furor Over Trump’s Drug Pricing Plan

Did the head of the Office and Management & Budget really endorse Part D rebates? Like so much about the Trump Administration’s response to drug pricing, there is probably a lot less to the story than it sounds.

Generic Priority Review Expanded In Senate User Fee Bill

Amendment added during markup would require eight-month review of ANDAs for shortage drugs and those with limited competition, as well as pre-submission meetings.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB002070

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel